Hims & Hers Rallies on Peptides

Hims & Hers is positioning itself to capitalize on a potential regulatory shift that would allow compounding pharmacies to offer more peptide treatments.

Health Secretary Robert F. Kennedy Jr. has reportedly been pushing for broader access to these substances, which are used for everything from anti-aging to muscle recovery.

Analysts believe that if the FDA relaxes its 2023 ban on several unproven peptides, Hims could see a significant boost in its long-term growth prospects.

The company's stock has already benefited from the ongoing craze for weight-loss medications like semaglutide.